What is the treatment for dermatomyositis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for dermatomyositis should involve a combination of high-dose corticosteroids and a steroid-sparing agent, such as methotrexate, azathioprine, or mycophenolate mofetil, as the initial drug regimen, followed by a tapering course of corticosteroids, as recommended by the most recent and highest quality study 1.

Key Treatment Components

  • High-dose corticosteroids, such as prednisone, starting at 0.5-1 mg/kg/day, which is maintained until symptoms improve and then gradually tapered over months 1
  • Immunossuppressive medications, including methotrexate (15-25 mg weekly), azathioprine (1-3 mg/kg/day), or mycophenolate mofetil (1-3 g daily in divided doses), to reduce steroid dependence or for patients who don't respond adequately to steroids 1
  • For severe or refractory cases, intravenous immunoglobulin (IVIG) at 2 g/kg divided over 2-5 days may be used monthly, or rituximab (1000 mg IV given twice, two weeks apart) may be considered as an adjunctive therapy 1

Supportive Care

  • Physical therapy to maintain muscle strength and prevent contractures 1
  • Sun protection, including the use of broad-spectrum sunscreen (SPF 50+), wearing protective clothing, and limiting sun exposure, as UV exposure can trigger flares 1
  • Regular monitoring for disease complications, including interstitial lung disease and associated malignancies, is important as dermatomyositis is an autoimmune inflammatory myopathy that affects skin and muscles through immune-mediated processes targeting muscle fibers and blood vessels 1

From the FDA Drug Label

  1. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis)
  • Treatment for Dermatomyositis: The drug label indicates that prednisone can be used as treatment for systemic dermatomyositis (polymyositis) during an exacerbation or as maintenance therapy in selected cases 2.
  • Key Points:
    • Prednisone is used for short-term administration to tide the patient over an acute episode or exacerbation.
    • It can be used as maintenance therapy in selected cases.

From the Research

Treatment for Dermatomyositis

The treatment for dermatomyositis typically involves a combination of medications to manage the symptoms and slow the progression of the disease. Some of the treatment options include:

  • Corticosteroids, such as prednisone, to reduce inflammation and suppress the immune system 3, 4, 5
  • Immunosuppressive medications, such as azathioprine or methotrexate, to help reduce the immune system's attack on the muscles and skin 5
  • Intravenous immunoglobulin (IVIG) to help reduce inflammation and improve muscle strength 3, 6
  • Hydroxychloroquine to improve cutaneous lesions 7
  • Rituximab, mycophenolate mofetil, or tacrolimus in case of treatment failure 5

Treatment Response

The response to treatment can vary depending on the individual and the severity of the disease. Some studies have shown that:

  • High-dose prednisone followed by slow tapering can be effective in resolving myositis 4
  • IVIG can improve muscle strength and reduce inflammation 3, 6
  • Hydroxychloroquine can improve cutaneous lesions, but may not have a beneficial effect on myositis 7

Treatment Strategies

The treatment strategy for dermatomyositis often involves a combination of medications and may need to be adjusted over time. Some studies suggest that:

  • Most patients require treatment with oral high-dose prednisone combined with azathioprine or methotrexate to facilitate early tapering of prednisone 5
  • IVIG can be tried in case of treatment failure, followed by rituximab, mycophenolate mofetil, or tacrolimus depending on the specific clinical situation 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of dermatomyositis with intravenous gammaglobulin.

The American journal of medicine, 1991

Research

Dermatomyositis: a dermatology-based case series.

Journal of the American Academy of Dermatology, 1998

Research

Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.

Journal of the American Academy of Dermatology, 1984

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.